By Sabela Ojea
Atara Biotherapeutics said it plans to submit a biologics license application for tabelecleucel following productive conversations with the U.S. Food and Drug Administration.
The biopharmaceutical company and the FDA are now aligned and it expects to submit the application in the second quarter of 2024, Atara Biotherapeutics…
Read the full article here
